← Back to Search

Gene Therapy

HMI-102 for Pyridoxine-Dependent Epilepsy (pheNIX Trial)

Phase 1 & 2
Waitlist Available
Led By Olaf A Bodamer, M.D.
Research Sponsored by Homology Medicines, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 24-28
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new gene therapy called HMI-102 in adults with PKU, a genetic condition. The therapy aims to help their bodies produce an enzyme they are missing. Participants will receive the treatment and be monitored over several months. HMI-102 is designed to treat PKU by delivering the PAH gene to produce the missing enzyme.

Eligible Conditions
  • Pyridoxine-Dependent Epilepsy (PDE)
  • Tetrahydrobiopterin Deficiency
  • Phenylketonuria

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 24-28
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 24-28 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from baseline in 12-lead electrocardiograms (ECGs), vital signs, physical examinations (Dose Escalation Phase)
Change from baseline in Plasma Phe Concentration (Dose Escalation Phase)
Change from baseline in clinical laboratory values (Dose Escalation Phase)
+3 more
Secondary study objectives
Change from baseline in total protein intake at Week 52 post-administration of HMI-102 (Dose Expansion Phase)
Incidence and severity of treatment-emergent adverse events (TEAEs) (Dose Expansion Phase)
Incidence of plasma Phe concentration thresholds up to Week 28 post administration of HMI-102 (Dose Expansion Phase)
+1 more
Other study objectives
Phenylketonuria Quality of Life Questionnaire (PKU-QOL)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

6Treatment groups
Experimental Treatment
Group I: Expansion Phase Second Dose levelExperimental Treatment1 Intervention
Expansion Phase Second Dose Level of HMI-102 delivered intravenously one time
Group II: Expansion Phase First Dose levelExperimental Treatment1 Intervention
Expansion Phase First Dose Level of HMI-102 delivered intravenously one time
Group III: Delayed Treatment ControlExperimental Treatment1 Intervention
Delayed Treatment Control Arm
Group IV: Cohort 3Experimental Treatment1 Intervention
Dose Level 3 of HMI-102 delivered intravenously one time
Group V: Cohort 2Experimental Treatment1 Intervention
Dose Level 2 of HMI-102 delivered intravenously one time
Group VI: Cohort 1Experimental Treatment1 Intervention
Dose Level 1 of HMI-102 delivered intravenously one time

Find a Location

Who is running the clinical trial?

Homology Medicines, IncLead Sponsor
5 Previous Clinical Trials
12,031 Total Patients Enrolled
Olaf A Bodamer, M.D.Principal InvestigatorBoston Children's Hospital
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top